WO2004096849A3 - Peptide-based cytokine/chemokine vaccines against allergy - Google Patents

Peptide-based cytokine/chemokine vaccines against allergy Download PDF

Info

Publication number
WO2004096849A3
WO2004096849A3 PCT/CA2004/000610 CA2004000610W WO2004096849A3 WO 2004096849 A3 WO2004096849 A3 WO 2004096849A3 CA 2004000610 W CA2004000610 W CA 2004000610W WO 2004096849 A3 WO2004096849 A3 WO 2004096849A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
chemokines
cytokines
chemokine
binding sites
Prior art date
Application number
PCT/CA2004/000610
Other languages
French (fr)
Other versions
WO2004096849A2 (en
Inventor
Zhikang Peng
Kent Hayglass
Original Assignee
Univ Manitoba
Zhikang Peng
Kent Hayglass
Manitoba Inst Of Child Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba, Zhikang Peng, Kent Hayglass, Manitoba Inst Of Child Health filed Critical Univ Manitoba
Publication of WO2004096849A2 publication Critical patent/WO2004096849A2/en
Publication of WO2004096849A3 publication Critical patent/WO2004096849A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to the methods and materials involved in the prevention and treatment of allergy. The inventors have identified a number of key peptides derived from the receptor binding sites of Th2 cytokines/chemokines such as interleukin (IL)-4, -5, -9, -13, -25, eotaxin and TARC and from the cytokine/chemokine binding sites of their receptors such as IL-4Rα. These peptides are made immunogenic by linkage to a carrier protein such as the Hepatitis B surface antigen (HBsAg) or the Hepatitis core antigen (HBcAg) via construction of a fusion protein or chemical methods to form a vaccine compound. The vaccine which consists of the vaccine compound and a human adjuvant can be used to down regulate allergic responses induced by over-expressed Th2 cytokines and chemokines. The vaccine itself or in combination with its DNA form induces autoantibodies which bind to cytokines/chemokines, thus reversing and preventing allergic responses for a long term.
PCT/CA2004/000610 2003-04-25 2004-04-26 Peptide-based cytokine/chemokine vaccines against allergy WO2004096849A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46527603P 2003-04-25 2003-04-25
US60/465,276 2003-04-25

Publications (2)

Publication Number Publication Date
WO2004096849A2 WO2004096849A2 (en) 2004-11-11
WO2004096849A3 true WO2004096849A3 (en) 2005-07-14

Family

ID=33418218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2004/000610 WO2004096849A2 (en) 2003-04-25 2004-04-26 Peptide-based cytokine/chemokine vaccines against allergy

Country Status (1)

Country Link
WO (1) WO2004096849A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
EP2365983B1 (en) * 2008-11-17 2016-12-28 Københavns Universitet Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
EP2480251A1 (en) 2009-09-21 2012-08-01 Peptinov SAS Carrier conjugates of il-23-peptides and their induced antibodies
CN102233137B (en) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 Recombinant plasmid DNA vaccine composition for treating Hepatitis B
AU2011289529A1 (en) 2010-08-09 2013-03-07 Cyvax, Inc. Methods and compositions for preventing a condition
CN107106668A (en) * 2014-12-10 2017-08-29 华西亚生医有限公司 The novel protein structure produced for the potent antibodies in immune

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6358509B1 (en) * 1989-12-20 2002-03-19 Schering Corporation Antibody antagonists of human interleukin-4
WO2002070711A1 (en) * 2001-03-03 2002-09-12 Glaxo Group Limited Vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358509B1 (en) * 1989-12-20 2002-03-19 Schering Corporation Antibody antagonists of human interleukin-4
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
WO2002070711A1 (en) * 2001-03-03 2002-09-12 Glaxo Group Limited Vaccine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLARKE B E ET AL: "IMPROVED IMMUNOGENICITY OF A PEPTIDE EPITOPE AFTER FUSION TO HEPATITIS B CORE PROTEIN", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 330, 26 November 1987 (1987-11-26), pages 381 - 384, XP002035982, ISSN: 0028-0836 *
GAVETT S H ET AL: "INTERLEUKIN 12 INHIBITS ANTIGEN-INDUCED AIRWAY HYPERRESPONSIVENESS,INFLAMMATION, AND TH2 CYTOKINE EXPRESSION IN MICE", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 182, no. 5, 1 November 1995 (1995-11-01), pages 1527 - 1536, XP000676698, ISSN: 0022-1007 *
HERTZ M ET AL: "Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 OCT 2001, vol. 167, no. 7, 1 October 2001 (2001-10-01), pages 3792 - 3799, XP002307680, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
WO2004096849A2 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
IL190744A0 (en) Chimeric antigen containing hepatitis c virus polypeptide and fc fragment for eliciting an immune response
WO2005112991A3 (en) Vaccines
WO2006044923A3 (en) Yeast-based therapeutic for chronic hepatitis c infection
JP2006510347A5 (en)
DK1928492T3 (en) Immunological applications of immunomodulatory compounds for vaccine and therapy for infectious diseases
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
RU2007126553A (en) ORDERED SERIES OF IL-15 ANTIGENES AND THEIR APPLICATION
WO2007149518A3 (en) Dna composition against tumor stromal antigen fap and methods of use thereof
DK1406656T3 (en) Methods for administering anti-TNF alpha antibodies
DK1572748T3 (en) Humanized antibody (H14.18) of mouse 14.18 antibody that binds to GD2 and its fusion protein with IL-2
DK1584685T3 (en) Tumor-associated antigen derivatives from the Mage family, used to prepare fusion proteins with T helper epitopes and vaccine compositions
Li et al. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection
WO2007015704A3 (en) Modified bacteriophage vectors and uses thereof
HUP0200128A2 (en) Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
WO2020132091A9 (en) Antibodies that neutralize hepatitis b virus and uses thereof
WO2004096849A3 (en) Peptide-based cytokine/chemokine vaccines against allergy
CA2674837A1 (en) Anti-ige vaccines
WO2006124451A3 (en) Anti-il-13 antibodies, compositions, methods and uses
WO2007016598A3 (en) Influenza vaccine compositions and methods of use thereof
Li et al. Research progress of therapeutic vaccines for treating chronic hepatitis B
AU2003246373A8 (en) Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions
EP1846026A4 (en) Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
WO2005007673A3 (en) Immunogenic peptides
MY161452A (en) Dengue virus capsid protein which induces a protective response and pharmaceutical composition
TW200619228A (en) Immunogenic compositions of staphylococcus epidermidis polypeptide antigens

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase